Non-invasive cardiovascular risk assessment platform: PreScreen for mass populations (no blood tests; estimates central systolic BP ≈80% accuracy from self‑reported/estimated biometrics). ProScreen is an in‑pharmacy, Pulse Wave Analysis service in Australia and New Zealand (~99% cSBP accuracy) providing real‑time arterial stiffness and inflammation insights via a dynamic algorithm using age, gender, height, waist, heart rate and blood pressure.